Montanide® ISA 720 vaccines: Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

Vaccine

Volumn 23, Issue 19, 2005, Pages 2530-2539

  Miles, Aaron P ^a   McClellan, Holly A ^a   Rausch, Kelly M ^a   Zhu, Daming ^a   Whitmore, Michael D ^a,b   Singh, Sanjay ^a   Martin, Laura B ^a   Wu, Yimin ^a   Giersing, Birgitte K ^a,c   Stowers, Anthony W ^a,d   Long, Carole A ^a   Saul, Allan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b AMGEN INC   (United States)

^c Malaria Vaccine Initiative   (United States)

^d CSL LIMITED   (Australia)

Author keywords

Adjuvant; Montanide ISA 720; Recombinant protein; Vaccine

Indexed keywords

GLYCINE; GLYCYLGLYCINE; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; UNCLASSIFIED DRUG; ANTIGEN; DRUG DERIVATIVE; MANNITOL; MANNITYL OLEATE; OLEIC ACID; PARASITE ANTIGEN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; EMULSION; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; TEMPERATURE; ANIMAL; ANIMAL MODEL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; STANDARD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS; ANTIGENS, PROTOZOAN; DRUG STABILITY; DRUG STORAGE; EMULSIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MANNITOL; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; OLEIC ACIDS; QUALITY CONTROL; RECOMBINANT PROTEINS; TEMPERATURE; VACCINES;

EID: 20044388097     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.08.049     Document Type: Article

References (23)

1. W.R. Ballou, S.L. Hoffman, and J.A. Sherwood Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine Lancet 1 8545 1987 1277 1281
2. R. Amador, A. Moreno, and V. Valero The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity Vaccine 10 3 1992 179 184
3. P.L. Alonso, T. Smith, and J.R. Schellenberg Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania Lancet 344 8931 1994 1175 1181
4. U. D'Alessandro, A. Leach, and C.J. Drakeley Efficacy trial of malaria vaccine SPf66 in Gambian infants Lancet 346 8973 1995 462 467
5. W.A. Keitel, K.E. Kester, and R.L. Atmar Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid Vaccine 18 5/6 1999 531 539
6. O. Kashala, R. Amador, and M.V. Valero Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21 Vaccine 20 17/18 2002 2263 2277
7. D.C. Kaslow Transmission-blocking vaccines Chem Immunol 80 2002 287 307
8. J. Aucouturier, L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines Expert Rev Vaccines 1 1 2002 111 118
9. D. Pye, K.L. Vandenberg, and S.L. Dyer Selection of an adjuvant for vaccination with the malaria antigen, MSA-2 Vaccine 15 9 1997 1017 1023
10. G.W. Lawrence, A. Saul, A.J. Giddy, R. Kemp, and D. Pye Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720 Vaccine 15 2 1997 176 178
11. A. Saul, G. Lawrence, and A. Smillie Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 adjuvant Vaccine 17 1999 3145 3159
12. B. Genton, I. Betuela, and I. Felger A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea J Infect Dis 185 6 2002 820 827
13. H. Toledo, A. Baly, and O. Castro A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers Vaccine 19 30 2001 4328 4336
14. W.J. Herbert The mode of action of mineral-oil emulsion adjuvants on antibody production in mice Immunology 14 3 1968 301 318
15. G. Lawrence, Q.Q. Cheng, and C. Reed Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers Vaccine 18 18 2000 1925 1931
16. J. Aucouturier, L. Dupuis, and V. Ganne Adjuvants designed for veterinary and human vaccines Vaccine 19 17-19 2001 2666 2672
17. M.C. Kennedy, J. Wang, and Y. Zhang In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response Infect Immun 70 12 2002 6948 6960
18. L. Zou, A.P. Miles, J. Wang, and A.W. Stowers Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials Vaccine 21 15 2003 1650 1657
19. H. Hisaeda, A.W. Stowers, and T. Tsuboi Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes Infect Immun 68 12 2000 6618 6623
20. S. Singh, M.C. Kennedy, C.A. Long, A.J. Saul, L.H. Miller, and A.W. Stowers Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1 Infect Immun 71 12 2003 6766 6774
21. Sambrook J, Fritsch EF, Maniatis T. In: Molecular cloning: a laboratory manual, vols. 1-3. New York: Cold Spring Harbor Laboratory Press; 1989. p. 18.56.
22. A. Kibbe Handbook of pharmaceutical excipients 3rd ed. 2000 American Pharmaceutical Association and the Pharmaceutical Press London
23. L. Rastrelli, S. Passi, F. Ippolito, G. Vacca, and F. De Simone Rate of degradation of alpha-tocopherol, squalene, phenolics, and polyunsaturated fatty acids in olive oil during different storage conditions J Agric Food Chem 50 20 2002 5566 5570